<DOC>
	<DOCNO>NCT00501995</DOCNO>
	<brief_summary>Systemic Sclerosis ( Scleroderma ) vary greatly clinical manifestation , mode presentation , course . The natural history chronic autoimmune disease range benign fatal . Patients classify limited diffuse scleroderma define degree skin involvement . Patients limited disease ( e.g . C.R.E.S.T . syndrome ) generally mild disease normal survival . However , patient diffuse cutaneous scleroderma often severe multi-system disease devastate emotionally physically associate 60-70 % five year survival 40-50 % 10 year survival . No therapy proven effective treatment scleroderma . Strategy treat scleroderma include attempt prevent fibrosis drug interfere collagen metabolism , attempt modify disease process immunosuppression attempt alter disease vasoactive drug . High dose corticosteroid immunosuppressive drug ( e.g . chlorambucil , 5-fluorouracil , methotrexate , cyclophosphamide , cyclosporine ) use conventional dos proven curative , show benefit inflammatory feature disease ( e.g . arthritis , myositis , fibrosing alveolitis ) . Both allogeneic autologous bone marrow transplantation ( BMT ) show modify instance reverse variety animal model autoimmune disease . This prompt many investigator propose use peripheral blood stem cell transplantation ( PBSCT ) treatment autoimmune disease include scleroderma . Unfortunately , approach risk infuse untreated autoreactive lymphocyte clone immunoablative preparative regimen . We previously demonstrate high-dose cyclophosphamide without BMT induce durable complete remission another autoimmune disease , severe aplastic anemia . Recent data high dose cyclophosphamide show induce complete remission autoimmune hematologic disorder . The objective study determine whether high dose cyclophosphamide induce durable remission scleroderma patient life-threatening disease , determine toxicity high dose cyclophosphamide high risk scleroderma patient .</brief_summary>
	<brief_title>High Dose Cyclophosphamide Treatment Scleroderma</brief_title>
	<detailed_description>Study design The study open-label , single-site trial single exposure high-dose cyclophosphamide without stem cell rescue . Each patient follow doctor eliminate interobserver skin score variation . Baseline measurement include comprehensive laboratory study include complete blood count differential , comprehensive metabolic panel , urine analysis culture , quantitative immunoglobulin , antibody hepatitis B core surface antigens antibody hepatitis C , human immunodeficiency , herpes , varicella , Epstein-Barr viruses ; rapid plasma reagin test , chest x-ray high-resolution compute tomography ( HRCT ) scan lung , pulmonary function testing , electrocardiogram , echo MUGA scan . The primary clinical efficacy end point modify Rodnan skin score ( mRSS ) .24 A 25 % sustained improvement mRSS point follow-up consider clinically important successful outcome.25 Secondary outcome measure include Health Assessment Questionnaire-Disability Index ( HAQ-DI ) physician global assessment ( PGA ) determine visual analogue scale scale 0 100 . Values percentage predict lung volume reference NHANES/Hanikson et al26 DLCO Knudson et al.27 The disease duration define time first non-Raynaud 's symptom relate scleroderma study entry . Treatment protocol Cyclophosphamide ( 50 mg/kg ) administer intravenously 1 hour daily four consecutive day ( 200 mg/kg total ) Hickman catheter . The dose cyclophosphamide base ideal body weight determine Metropolitan Life tables.28 29 If patient 's actual weight less ideal body weight , actual body weight use calculate cyclophosphamide dose . Intravenous mesna ( 10 mg/kg ) give 30 minute cyclophosphamide 3 , 6 8 hour cyclophosphamide administer prophylaxis haemorrhagic cystitis . Intravenous ondansetron ( 32 mg ) administer 1 hour dose cyclophosphamide . Six day last dose cyclophosphamide , patient receive granulocyte colony-stimulating factor ( 5 µg/kg/day ) neutrophil count 1×109/l two consecutive day . Prophylactic antibiotic support , consist fluconazole ( 400 mg/day ) , norfloxacin ( 400 mg/day ) , valaciclovir ( 500 mg twice day , antibody herpes simplex present ) , give begin day last dose cyclophosphamide continue neutrophil count exceed 0.5×109/l . Dapsone ( 100 mg three time week 6 month ) trimethoprim-sulfamethoxazole ( 80/400 mg three time week 6 month ) administer Pneumocystis carinii prophylaxis . Packed red blood cell ( leucocyte-poor ) transfusion administer maintain haematocrit level &gt; 25 % . Platelet transfusion give bleed maintain platelet count &gt; 10×109/l , . All blood product irradiate ( &gt; 2000 rad ) prevent graft versus host disease .</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Meet establish criterion diagnosis diffuse cutaneous scleroderma evidence moderately severe organ damage clinical evidence active disease . Patients diffuse scleroderma evidence active fibrosing alveolitis manifest either great 10 % decline force vital capacity diffuse capacity define normal value baseline measurement . Patients severe deform localized scleroderma ( generalized morphea , liner morphea , keloid bullous scleroderma ) threaten capacity function normally society . Age le 18 year 70 year Any risk pregnancy Cardiac ejection fraction &lt; 45 % Serum creatinine &gt; 3.0 Patients preterminal moribund Bilirubin &gt; 2.0 , transaminase &gt; 2x normal FVC , FEV1 ( 5/30/01 ) &lt; 50 % predict</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>High Dose Cyclophosphamide</keyword>
	<keyword>Systemic Sclerosis</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>immunoablation</keyword>
</DOC>